These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10942387)

  • 41. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB; Moukhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase.
    Bokarewa M; Tarkowski A
    Thromb Haemost; 2004 May; 91(5):991-9. PubMed ID: 15116261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots.
    Lian Q; Szarka SJ; Ng KK; Wong SL
    J Biol Chem; 2003 Jul; 278(29):26677-86. PubMed ID: 12736246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombolytic properties of staphylokinase.
    Matsuo O; Okada K; Fukao H; Tomioka Y; Ueshima S; Watanuki M; Sakai M
    Blood; 1990 Sep; 76(5):925-9. PubMed ID: 2118398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
    Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen HR
    Biochim Biophys Acta; 1994 Feb; 1204(2):235-42. PubMed ID: 8142464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
    Moons L; Vanlinthout I; Roelants I; Moreadith R; Collen D; Rapold HJ
    Toxicol Pathol; 2001; 29(3):285-91. PubMed ID: 11442014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
    Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
    Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of staphylokinase by enzyme-linked immunosorbent assay using monoclonal antibodies.
    Mike A; Ohya Y; Ohwaki M; Sakai M; Sako T; Watanabe T; Yokokura T
    Biol Pharm Bull; 1994 May; 17(5):564-7. PubMed ID: 7522729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
    Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
    Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase.
    Liu J; Wang Z; He J; Wang G; Zhang R; Zhao B
    Acta Biochim Biophys Sin (Shanghai); 2014 Sep; 46(9):782-91. PubMed ID: 25098624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Thrombolytic effects of recombinant staphylokinase on coronary thrombosis in miniature pigs].
    Li G; Fang XL; Ren Z; Li KQ; Zhou SH; Hu DQ; Wu GQ; Wang TL; Li WP
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 Jul; 36(4):369-374. PubMed ID: 33167101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
    Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
    Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
    Lijnen HR; Stassen JM; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D
    Thromb Haemost; 1991 Oct; 66(4):468-73. PubMed ID: 1796398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
    Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
    PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
    Kochanowski R; Kotlowski R; Szweda P
    Appl Biochem Biotechnol; 2007; 141(2-3):321-33. PubMed ID: 18025559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.
    Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L
    MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.